Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials

Cancer Treatment Reviews(2025)10.1016/j.ctrv.2025.103002Source: DataRank Database

Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials is a research paper published in Cancer Treatment Reviews (2025). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

2 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.30)OA: closedTopics (21)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Kennedy Yao Yi Ng ORCID,Raghav Sundar ORCID,Samuel J. Klempner ORCID,Joseph J. Zhao ORCID

Live enrichment

PubMed:40779895 OpenAlex:https://openalex.org/W4413031601

National University of Singapore

Grant: NUHSRO/2024/008/RO5 + 6/Seed-Sep23/01

SingHealth

Grant: AM/HRT025/2023

Government of Singapore Ministry of Health

Grant: NMRC/CG/C027/2017_SHS

Dana Foundation

Dana-Farber/Harvard Cancer Center

National Medical Research Council

National Institutes of Health

National University Health System

FWCI

1.30

Citation Percentile

0.8%

Citation Trend

2025

2026

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S0305737225001240?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0305737225001240?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ctrv.2025.103002

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40779895

Fields of Study

Esophageal Cancer Research and TreatmentCancer Immunotherapy and BiomarkersCancer, Stress, Anesthesia, and Immune Response

MeSH Terms

Immune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsHumansStomach NeoplasmsRandomized Controlled Trials as TopicClinical Trials, Phase III as TopicPerioperative Care

Keywords

MedicinePerioperativeEsophageal cancerMeta-analysisOncologyInternal medicineCancerSurgeryGastroesophageal CancerImmune Checkpoint Inhibition

Sustainable Development Goals

SDG 0: Good health and well-being

Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials

FAIR Checklist

Authors (4)

Funding (8 grants)

Impact

Open Access

Topics